#Merck

A speedy overview of the major scientific findings presented at the International AIDS Conference in Amsterdam (AIDS 2018)

Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.

Among a group of largely HIV-positive gay and bi men, Zepatier (grazoprevir/elbasvir) boasted a 99 percent cure rate.

Merck’s investigational antiretroviral could one day be dosed only weekly among HIV-negative humans.

The annual scientific meeting on liver health revealed exciting new findings concerning the battle against the hep C epidemic.

The new drug application is for doravirine as both an individual tablet and part of a combination tablet.

Merck’s hepatitis C treatment cured almost all those with stages 3 through 5 of chronic kidney disease in a VA database.

The president tweeted a swift retort to the African-American head of Merck.

Until now, Isentress (raltegravir) had been available only as a twice-daily drug.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Used as a part of a multidrug HIV regimen, the investigational doravirine is also better for cholesterol levels than Norvir/Prezista.

The U.S. Food and Drug Administration (FDA) has approved Merck’s once-daily fixed-dose combination tablet Zepatier (grazoprevir/elbasvir)

Here’s what’s in store this year for new hepatitis C therapies, as well as approvals for new uses of existing treatments.